首页> 中文期刊> 《国际消化病杂志》 >替吉奥联合腹腔热灌注顺铂、甘露聚糖肽对晚期胃癌合并腹腔积液患者的疗效观察

替吉奥联合腹腔热灌注顺铂、甘露聚糖肽对晚期胃癌合并腹腔积液患者的疗效观察

         

摘要

目的 研究替吉奥联合腹腔热灌注顺铂、甘露聚糖肽对晚期胃癌合并腹腔积液患者的疗效.方法 选取2012年2月至2015年3月在深圳市第四人民医院接受治疗的晚期胃癌合并腹腔积液患者84例,以数字法随机分为A、B、C组,每组各28例.A组予替吉奥口服联合腹腔热灌注顺铂+甘露聚糖肽,B组予腹腔热灌注顺铂+甘露聚糖肽,C组予腹腔热灌注顺铂化学治疗,对比3组的疗效.结果 A组治疗有效率、生活质量总改善率显著高于B组和C组,A组患者6个月生存率显著高于B组(P均<0.05).结论 替吉奥联合腹腔热灌注顺铂、甘露聚糖肽对晚期胃癌合并腹腔积液患者的疗效显著,且预后较好.%Objective This paper investigates the effect of S-1 combined with cisplatin and mannatide delivered by hyperthermic intraperitoneal chemotherapy (HIPEC) on patients with advanced gastric cancer and peritoneal effusion.Methods Eighty four patients with advanced gastric cancer and peritoneal effusion from February 2012 to March 2015 in the FourthPeople′s Hospital of Shenzhen were divided into 3 groups randomly (n=28).Group A received S-1 orally together with cisplatin and mannatide delivered by HIPEC.Group B were treated with cisplatin and mannatide delivered by HIPEC.Group C took cisplatin delivered by HIPEC respectively.The curative effect of the three groups was compared.Results The effective rate and improvement rate of group A were significantly higher than group B and group C.The survival rate of 6 monthes of group A separately was significantly higher than group B (P<0.05).Conclusion The effective rate and prognosis of the patients who were treated with S-1 combined with cisplatin and mannatide delivered by HIPEC is good.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号